Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

Anti-PD-1/PD-L1 antibodies have shown encouraging clinical activity in advanced GC/GEJC. Results from ongoing phase 3 trials are needed to further evaluate the potential roles of these agents within the continuum of care.